$CLB

Core Laboratories Inc. /DE/

0
2
0

No SEC Form 4 filings for $CLB in the last 30 days.

Low

Core Laboratories Shareholders Back Directors, Auditor and Pay

Core Laboratories Inc. held its Annual Meeting of Shareholders on May 12, 2026, where investors re-elected two Class I directors, Harvey Klingensmith and Curtis Anastasio, to terms running until 2029. Shareholders also ratified KPMG LLP as the independent registered public accountant for 2026 and supported the company's executive compensation philosophy. This indicates broad support for Core Laboratories' governance and leadership structure, despite an AI analyst's "Neutral" rating on the stock due to weak technicals but partially offset by improved leverage and solid margins.

1 Energy Stock Worth Your Attention and 2 We Question

This article analyzes the energy sector, which has seen significant gains recently, and recommends one stock to buy while advising against two others. ConocoPhillips (COP) is identified as a strong buy due to its market-beating returns, increasing market share, strong revenue growth, and free cash flow margin. Conversely, SLB (SLB) and Core Laboratories (CLB) are noted as stocks to sell due to high extraction costs, low gross margins, slower revenue growth, and unfavorable valuations.

P/E Ratio Insights for Core Laboratories - Core Laboratories ( NYSE:CLB )

In the current session, Core Laboratories Inc. ( NYSE:CLB ) is trading at $14.95, after a 0.60% drop. Over the past month, the stock decreased by 6.33%, and in the past year, by 26.54%. With performance like this, long-term shareholders are more likely to start looking into the company's ...